ľ¹Ï¸£ÀûÓ°ÊÓ

The treatment of cancer patients has been improved by enhanced understanding of cancer. The more personalized care resulted in an improved survival of cancer patients. The research in this thesis focusses on different strategies to further improve the treatment of cancer patients.

To illustrate, tumor-specific RNA from blood platelets may enable for improved diagnostics of cancer of the soft tissues. Furthermore, cell lines of these patients could be used to predict treatment response to avert ineffective and toxic therapies.

Additionally, new treatment combinations could enhance the effectivity. For example, chemotherapy could make the tumor more vulnerable for immunotherapy. Another strategy is the combination of immunotherapy with newer immunotherapeutic compounds directed against GITR or OX-40.

Also a new dosing strategy, in which monoclonal antibodies are prescribed in a fixed dose in oncology, could enhance the safety and cost-effectiveness.

Another important point is the timing of treatment. Chemotherapy before surgery could improve the outcome of surgery in angiosarcoma. However, the effect on survival could not be determined based on the limited available literature.

Lastly, we searched for new targets in the treatment of soft tissue tumors, based on tumor characteristics. For instance, propranolol could be used in the treatment of angiosarcoma or PARP-inhibitors in the treatment of soft tissue tumors.